DrugPatentWatch Database Preview
Investigational Drug Information for Defactinib
Email this page to a colleague
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 19 clinical trials for Defactinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 21st 2021.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Mesothelioma. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and National Cancer Institute (NCI).
There are seventeen US patents protecting this investigational drug and one hundred and eighty-nine international patents.
Summary for Defactinib
| US Patents | 17 |
| International Patents | 189 |
| US Patent Applications | 147 |
| WIPO Patent Applications | 129 |
| Japanese Patent Applications | 44 |
| Clinical Trial Progress | Phase 2 (2021-07-21) |
| Vendors | 53 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | National Cancer Institute (NCI) | Phase 2 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Verastem, Inc. | Phase 2 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Washington University School of Medicine | Phase 2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | ⤷ Try it Free | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | ⤷ Try it Free |
| Defactinib | ⤷ Try it Free | Methods of diagnosing and treating B cell acute lymphoblastic leukemia | The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA) | ⤷ Try it Free |
| Defactinib | ⤷ Try it Free | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | Australia | AU2014254394 | 2033-04-17 | ⤷ Try it Free |
| Defactinib | China | CN105378110 | 2033-04-17 | ⤷ Try it Free |
| Defactinib | China | CN106414768 | 2033-04-17 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
